NeuroOne White Paper Highlights StereoCED™ Platform's Potential to Address Scalability Barriers in CNS Drug Delivery

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) has released a white paper titled “StereoCED™ - A Scalable Platform for CNS Drug Delivery,” available for download from the Scientific Resources section of nmtc1.com. The document addresses a critical challenge facing the field of central nervous system (CNS) therapeutics: the need for efficient, reproducible methods to deliver drugs directly to the brain as cell and gene therapies and biologics advance toward commercialization.

Convection-enhanced delivery (CED) has been shown to bypass the blood-brain barrier and achieve targeted drug distribution, but current approaches often involve lengthy sequential infusions lasting 8 to 12 hours, which could become a significant bottleneck for widespread adoption. The StereoCED™ platform is being designed to circumvent these limitations by integrating with robotic stereotactic systems already standard in neurosurgical operating rooms. This integration aims to support simultaneous, multi-trajectory intracranial drug delivery through a streamlined robotic workflow, potentially reducing procedure time and enabling reproducible, scalable therapeutic delivery.

“Brain-delivered therapeutics are approaching an important inflection point,” said Dave Rosa, President and Chief Executive Officer of NeuroOne. “As these therapies move toward commercialization, certain intracranial infusion procedures lasting 8 to 12 hours may become a significant bottleneck to commercial adoption. We believe healthcare systems will need solutions that leverage established neurosurgical workflows, significantly reduce procedure time, and support scalable delivery across hospitals. StereoCED™ is being designed with those needs in mind, and we look forward to device availability for research and investigational clinical studies by fiscal year-end.”

The white paper underscores how the platform is intended to address key barriers to scalable commercial delivery of brain therapeutics by eliminating the need for specialized workflows and reducing procedure duration. The StereoCED™ drug delivery platform is currently under development and has not been cleared or approved by the U.S. Food and Drug Administration for commercialization. NeuroOne expects the device to be available for research and investigational clinical studies by the end of its fiscal year.

NeuroOne markets a minimally invasive electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. The company is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. For more information, visit nmtc1.com.